| Literature DB >> 20445798 |
Alison L Van Dyke1, Michele L Cote, Angela S Wenzlaff, Judith Abrams, Susan Land, Priyanka Iyer, Ann G Schwartz.
Abstract
In a population-based case-control study, we explored the associations between 42 polymorphisms in seven genes in this region and non-small cell lung cancer (NSCLC) risk among Caucasian (364 cases; 380 controls) and African American (95 cases; 103 controls) women. Two TERT region SNPs, rs2075786 and rs2853677, conferred an increased risk of developing NSCLC, especially among African American women, and TERT-rs2735940 was associated with a decreased risk of lung cancer among African Americans. Five of the 20 GHR polymorphisms and SEPP1-rs6413428 were associated with a marginally increased risk of NSCLC among Caucasians. Random forest analysis reinforced the importance of GHR among Caucasians and identified AMACR, TERT, and GHR among African Americans, which were also significant using gene-based risk scores. Smoking-SNP interactions were explored, and haplotypes in TERT and GHR associated with NSCLC risk were identified. The roles of TERT, GHR, AMACR and SEPP1 genes in lung carcinogenesis warrant further exploration.Entities:
Year: 2010 PMID: 20445798 PMCID: PMC2861408 DOI: 10.1155/2009/242151
Source DB: PubMed Journal: J Cancer Epidemiol ISSN: 1687-8558
Participant characteristics.
| Variable | Caucasians | African Americans | ||||
|---|---|---|---|---|---|---|
| Cases | Controls | Cases | Controls | |||
| 364 | 380 | 95 | 103 | |||
| Age (years): Mean (sd) | 61 (9) | 60 (9) | .08 | 58 (9) | 58 (9) | .83 |
| Smoking Status: | ||||||
| Never | 36 (10) | 194 (51) | 8 (8) | 48 (47) | ||
| Former | 132 (36) | 119 (32) | 24 (25) | 31 (30) | ||
| Current | 195 (54) | 64 (17) | < | 63 (66) | 23 (23) | |
| Pack-years among Smokers: Mean (sd) | 51 (30) | 26 (23) | < | 30 (22) | 23 (23) | .07 |
| History of COPD1: | ||||||
| No | 242 (66) | 326 (86) | 72 (76) | 90 (87) | ||
| Yes | 122 (34) | 54 (14) | < | 23 (24) | 13 (13) | |
| Family History of Lung Cancer: | ||||||
| No | 277 (76) | 334 (88) | 67 (71) | 92 (89) | ||
| Yes | 87 (24) | 46 (12) | < | 28 (29) | 11 (11) | |
| Regular Adult Aspirin Use: | ||||||
| Never | 272 (76) | 280 (74) | 77 (82) | 78 (76) | ||
| Ever | 86 (24) | 100 (26) | .47 | 17 (18) | 24 (24) | .35 |
| Years of Education: Mean (sd) | 13 (2) | 14 (3) | < | 12 (3) | 13 (2) | |
| BMI2: Mean (sd) | 26 (6) | 29 (7) | < | 27 (7) | 32 (8) | |
1Chronic obstructive pulmonary disease including chronic obstructive lung disease, emphysema, and chronic bronchitis. 2Body mass index = weight and height in kg/m2.
Associations between chromosome 5p SNPs and risk of NSCLC by race under a dominant model.
| Caucasians | African Americans | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene | SNP Identifier | Minor Allele Freq (%) Controls | Hap Map CEU Allele Freq | OR1 | Gene | Minor Allele Freq (%) Controls3 | Hap Map ASW Allele Freq | OR1 | Gene | Comparison of Variant Allele Freq. | |
| rs34847072 | 2912 bp 3′ of STP G/C | 0.37 | N/A | 0.93 (0.64–1.35) | 0.10 | N/A | 1.03 (0.43–2.47) | ||||
| rs10078 | 3152 bp 3′ of STP T/G | 0.22 | 0.18 | 0.84 (0.58–1.22) | .22 | 0.26 | 0.23 | 0.65 (0.32–1.31) | .08 | .34 | |
| rs2853690 | Ex16 + 203 G/A | 0.18 | 0.16 | 0.92 (0.62–1.36) | 0.34 | 0.29 | 0.81 (0.40–1.60) | ||||
| rs2075786 | IVS10 + 269 G/A | 0.33 | 0.40 | 1.17 (0.81–1.70) | 0.48 | N/A | |||||
| rs2853677 | IVS2-4455 A/G | 0.44 | 0.42 | 0.23 | 0.36 | ||||||
| rs27359402 | −1381 A/G | 0.49 | N/A | 0.99 (0.66–1.49) | N/A | .15 | |||||
| rs1801075 | −22844 T/C | 0.16 | 0.18 | 1.00 (0.68–1.49) | .06 | 0.16 | 0.12 | 1.12 (0.54–2.29) | 1.00 | ||
| rs63472 | S405S | 0.25 | 0.25 | 1.10 (0.76–1.58) | 0.48 | 0.68 (0.30–1.56) | |||||
| rs460700 | IVS4 + 2610 T/C | 0.23 | 0.30 | 0.79 (0.54–1.15) | 0.32 | N/A | 0.79 (0.40–1.57) | ||||
| rs26525112 | −3076 G/A | 0.42 | N/A | 1.34 (0.90–2.00) | .17 | N/A | 0.92 (0.34–2.48) | .25 | |||
| rs10380 | H622Y | 0.10 | 0.16 | 0.94 (0.59–1.49) | 0.33 | 0.28 | 1.06 (0.53–2.11) | ||||
| rs1802059 | A664A | 0.39 | 0.31 | 0.88 (0.61–1.28) | 0.26 | 0.32 | 1.02 (0.52–2.02) | ||||
| rs9332 | Ex15-526 G/A | 0.11 | 0.19 | 1.01 (0.65–1.56) | 0.37 | 0.33 | 1.01 (0.50–2.03) | ||||
| rs86592 | Ex15-405 A/T | 0.36 | 0.46 | 1.04 (0.72–1.51) | .81 | N/A | 0.90 (0.40–2.04) | .89 | |||
| rs2278008 | K277E | 0.26 | 0.20 | 1.14 (0.79–1.64) | 0.23 | 0.17 | 0.99 (0.48–2.05) | .36 | |||
| rs840409 | IVS4 + 3803 G/C | 0.12 | 0.13 | 1.03 (0.66–1.59) | 0.10 | .04 | 0.59 (0.23–1.52) | .65 | |||
| rs34677 | Q239H | 0.15 | 0.15 | 0.98 (0.66–1.48) | 0.11 | .05 | 0.88 (0.36–2.06) | .15 | |||
| rs2287939 | S201L | 0.28 | 0.27 | 1.18 (0.82–1.70) | 0.16 | 0.20 | 0.67 (0.31–1.44) | ||||
| rs109411122 | D175G | 0.48 | 0.44 | 1.20 (0.80–1.82) | 0.88 | 1.54 (0.18–13.08) | |||||
| rs346892 | IVS1 + 169 A/C | 0.18 | 0.17 | 1.03 (0.70–1.52) | .63 | 0.47 | 0.58 (0.27–1.25) | ||||
| rs2972395 | −165670 C/T | 0.21 | 0.10 | 0.88 (0.60–1.28) | 0.22 | N/A | 1.00 (0.48–2.08) | .83 | |||
| rs2940930 | −160465 G/A | 0.36 | 0.36 | 0.76 (0.52–1.11) | 0.14 | 0.16 | 1.72 (0.84–3.53) | ||||
| rs7732059 | −142504 G/C | 0.22 | N/A | 1.29 (0.90–1.87) | 0.32 | N/A | 1.30 (0.65–2.59) | ||||
| rs1858136 | IVS1 + 12052 G/C | 0.21 | 0.10 | 0.86 (0.59–1.26) | 0.26 | N/A | 0.69 (0.34–1.40) | .15 | |||
| rs29724182 | IVS1 + 59636 T/C | 0.48 | 0.50 | 1.12 (0.74–1.72) | 0.65 | 0.66 (0.23–1.91) | |||||
| rs2972419 | IVS1 + 59820 G/A | 0.21 | 0.15 | 0.93 (0.63–1.36) | 0.22 | 0.29 | 0.98 (0.47–2.02) | .87 | |||
| rs29409442 | IVS1 + 65085 A/C | 0.46 | 0.49 | 1.25 (0.83–1.89) | 0.56 | 1.14 (0.48–2.72) | |||||
| rs29723922 | IVS1 − 70131 A/C | 0.41 | N/A | 1.30 (0.87–1.93) | N/A | 1.07 (0.46–2.52) | |||||
| rs33939197 | IVS1− 69908 T/C | 0.19 | N/A | 1.29 (0.88–1.87) | 0.16 | N/A | 0.86 (0.39–1.90) | .34 | |||
| rs29409132 | IVS1− 66349 G/T | 0.46 | 0.47 | 1.25 (0.83–1.89) | N/A | 0.60 (0.20–1.82) | |||||
| rs7735889 | IVS1− 3767 A/G | 0.25 | 0.34 | 1.10 (0.76–1.58) | 0.47 | 0.54 (0.23–1.30) | |||||
| rs7712701 | IVS2 + 4144 C/A | 0.23 | N/A | 1.20 (0.83–1.74) | N/A | 0.81 (0.33–2.00) | |||||
| rs28943882 | IVS2 + 29065 C/T | 0.17 | 0.21 | 1.16 (0.80–1.70) | 0.42 | 0.27 | 1.06 (0.52–2.15 | ||||
| rs6873545 | IVS3 + 2059 T/C | 0.26 | 0.28 | 0.45 | 0.58 | 1.12 (0.53–2.38) | |||||
| rs4451056 | IVS3 + 26148 G/C | 0.15 | 0.18 | 0.18 | N/A | 0.69 (0.33–1.45) | .31 | ||||
| rs6878512 | IVS3− 21121 C/T | 0.15 | 0.16 | 0.23 | N/A | 0.68 (0.34–1.38) | |||||
| rs68975302 | IVS3− 21055 T/C | 0.26 | N/A | N/A | 0.97 (0.42–2.28) | ||||||
| rs61792 | G186G | 0.26 | 0.29 | 0.64 | 0.91 (0.33–2.48) | ||||||
| rs29727802 | IVS8 + 1229 C/T | 0.25 | 0.26 | N/A | 0.78 (0.30–2.00) | ||||||
| rs6180 | Ex10 + 685 A/C | 0.47 | 0.45 | 0.73 (0.48–1.10) | .06 | 0.35 | 0.29 | 1.00 (0.49–2.03) | |||
| rs6413428 | Ex5 + 710 A/G | 0.23 | 0.26 | 0.34 | 0.38 | 0.70 (0.34–1.42) | |||||
| rs7579 | Ex5 + 626 C/T | 0.28 | 0.30 | 1.08 (0.75–1.55) | .06 | 0.16 | 0.17 | 0.78 (0.37–1.66) | .25 | ||
1Adjusted for age at diagnosis/interview, smoking pack-year history, years of education, family history of lung cancer, history of COPD, adult aspirin use (never/ever), and BMI. 2Adjusted for multiple comparisons via the Benjamini and Hochberg False Discovery Rate (FDR) method. 3The minor allele differed for Caucasians and African Americans for the SNPs for which minor allele frequencies are bolded.
Figure 1(a) Associations between chromosome 5p SNPs and NSCLC risk among Caucasians by chromosome position. Blue markers signify SNPs examined in our study. Pink markers indicate associations between rs401681 and lung cancer risk identified in the Rafner et al. (2009) and Wang et al. (2008) papers [2, 3]. The region of 5p surrounding rs401681 is expanded in the figure. Pink and blue rectangles surround rs401681 in CLPTM1L (aka CRR9) and the region of SNPs included in our study in TERT, respectively. (b) Associations between chromosome 5p SNPs and NSCLC risk among African Americans by chromosome position. Blue markers signify SNPs examined in our study.
Top ten variables classifying NSCLC case-control status by race on random forest analysis.
| Caucasians | African Americans | ||
|---|---|---|---|
| Variable | Mean decrease accuracy | Variable | Mean decrease accuracy |
| Smoking | 1.27 | Smoking | 2.01 |
| COPD History | 0.48 | Family History of Lung Cancer | 0.84 |
| Family History of Lung Cancer | 0.26 | rs2735940- | 0.39 |
| rs7735889- | 0.26 | rs2853690- | 0.32 |
| rs2972780- | 0.24 | rs1858136- | 0.28 |
| rs33939197- | 0.24 | rs840409- | 0.28 |
| rs2940944- | 0.20 | rs2972780- | 0.27 |
| rs2940913- | 0.20 | Regular Adult Aspirin Use | 0.26 |
| rs2972395- | 0.19 | rs2853677- | 0.25 |
| rs6878512- | 0.19 | rs7712701- | 0.24 |
Chromosome 5p SNPs and NSCLC Risk by Smoking History (Never/Ever) among Caucasians1.
| Never smokers | Ever smokers | ||||||
|---|---|---|---|---|---|---|---|
| SNP | OR2 (95% CI) | OR3 (95% CI) | |||||
| rs2853677- | AA | 5 | 61 | 1.00 | 76 | 60 | 1.00 |
| AG/GG | 29 | 132 | 2.43 (0.88–6.72) | 247 | 125 | ||
| rs6873545- | TT | 17 | 100 | 1.00 | 159 | 104 | 1.00 |
| TC/CC | 19 | 92 | 0.99 (0.47–2.09) | 168 | 82 | ||
| rs6897530- | TT | 17 | 103 | 1.00 | 158 | 105 | 1.00 |
| TC/CC | 19 | 90 | 1.02 (0.48–2.16) | 169 | 81 | ||
| rs6179- | GG | 18 | 106 | 1.00 | 154 | 101 | 1.00 |
| GA/AA | 18 | 88 | 0.93 (0.44–1.96) | 174 | 85 | ||
| rs2972780- | CC | 17 | 108 | 1.00 | 156 | 104 | 1.00 |
| CT/TT | 19 | 86 | 1.09 (0.52–2.31) | 172 | 82 | ||
| rs6413428- | AA | 17 | 116 | 1.00 | 165 | 108 | 1.00 |
| AG/GG | 19 | 77 | 1.33 (0.63–2.83) | 162 | 78 | ||
1Only SNPs associated with NSCLC risk among either never smokers or ever smokers are displayed. 2Adjusted for age at diagnosis/interview, years of education, family history of lung cancer, history of COPD, adult aspirin use, and BMI. 3Adjusted for age at diagnosis/interview, smoking pack-year history, years of education, family history of lung cancer, history of COPD, adult aspirin use, and BMI.